# OnCo record nct06894511 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06894511/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06894511", "NCT06894511" ;
  schema:name "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC"@en ;
  schema:alternateName "PSMAndARPI"@en ;
  schema:description "A phase 2 trial of FAP-2286, Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06894511/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06894511> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-09-11" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:drugs <https://onco.cc/drugs/fap-2286/>, <https://onco.cc/drugs/pluvicto/> ;
  onco:companies <https://onco.cc/companies/novartis/> .